Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Bibliography

• Horowitz MM, Gale RP, Sondel PM, Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925-35
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81
   PubMed Web of Science ®Google Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46
   PubMed Web of Science ®Google Scholar
• Becker ML, Near R, Mudgett-Hunter M, Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 1989;58:911-21
   PubMed Web of Science ®Google Scholar
• Goverman J, Gomez SM, Segesman KD, Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 1990;60:929-39
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-8
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987;149:960-8
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett-Hunter M, Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-83
   PubMed Web of Science ®Google Scholar
• Bird RE, Hardman KD, Jacobson JW, Single-chain antigen-binding proteins. Science 1988;242:423-6
   PubMed Web of Science ®Google Scholar
• Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997;45:131-6
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64:9160-6
   PubMed Web of Science ®Google Scholar
• Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 2000;7:128-34
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785-93
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Sircar R, T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997;113:1163-70
   PubMed Web of Science ®Google Scholar
• Pameijer CR, Navanjo A, Meechoovet B, Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther 2007;14:91-7
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005;28:203-11
   PubMed Web of Science ®Google Scholar
• Hombach AA, Schildgen V, Heuser C, T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 2007;178:4650-7
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180:7028-38
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-9
   PubMed Web of Science ®Google Scholar
• Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA 1991;88:8905-9
   PubMed Web of Science ®Google Scholar
• Hwu P, Shafer GE, Treisman J, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993;178:361-6
   PubMed Web of Science ®Google Scholar
• Ren-Heidenreich L, Mordini R, Hayman GT, Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother 2002;51(8):417-23
   PubMed Web of Science ®Google Scholar
• Nolan KF, Yun CO, Akamatsu Y, Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-41
   PubMed Web of Science ®Google Scholar
• Jakobsen MK, Restifo NP, Cohen PA, Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol 1995;17:222-8
   PubMed Web of Science ®Google Scholar
• Lou Y, Basha G, Seipp RP, Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin Cancer Res 2008;14:1494-501
   PubMed Web of Science ®Google Scholar
• Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 2007;67:1887-92
   PubMed Web of Science ®Google Scholar
• Vago L, Perna SK, Zanussi M, Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009;361:478-88
   PubMed Web of Science ®Google Scholar
• van Loenen MM, de Boer R, Amir AL, Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 2010;107:10972-7
   PubMed Web of Science ®Google Scholar
• Bendle GM, Linnemann C, Hooijkaas AI, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010;16:565-70, 1 page following 570
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 2010;18:1744-5
   PubMed Web of Science ®Google Scholar
• Gilham DE, O'Neil A, Hughes C, Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 2002;25:139-51
   PubMed Web of Science ®Google Scholar
• Hombach A, Koch D, Sircar R, A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 1999;6:300-4
   Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245-56
   PubMed Web of Science ®Google Scholar
• Park JR, Digiusto DL, Slovak M, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-33
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML. T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20:561-7
   PubMedGoogle Scholar
• Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-7
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Tumor-specific T cell activation by recombinant immunoreceptors: CD3zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3zeta signaling receptor molecule. J Immunol 2001;167:6123-31
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-5
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-84
   PubMed Web of Science ®Google Scholar
• Wang J, Jensen M, Lin Y, Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007;18:712-25
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009;183:5563-74
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106:3360-5
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453-64
   PubMed Web of Science ®Google Scholar
• Yvon E, Del Vecchio M, Savoldo B, Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009;15:5852-60
   PubMed Web of Science ®Google Scholar
• Wang J, Press OW, Lindgren CG, Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004;9:577-86
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8
   PubMed Web of Science ®Google Scholar
• Varmus H. Retroviruses. Science 1988;240:1427-35
   PubMed Web of Science ®Google Scholar
• Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983;33:153-9
   PubMed Web of Science ®Google Scholar
• Nordling D, Kaiser A, Reeves L. Release testing of retroviral vectors and gene-modified cells. Methods Mol Biol 2009;506:265-79
   PubMedGoogle Scholar
• Naldini L, Blomer U, Gallay P, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7
   PubMed Web of Science ®Google Scholar
• Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods 2003;275:251-5
   PubMed Web of Science ®Google Scholar
• Smith CA, Ng CY, Heslop HE, Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995;4:73-9
   PubMedGoogle Scholar
• Geurts AM, Yang Y, Clark KJ, Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-17
   PubMed Web of Science ®Google Scholar
• Wilson MH, Coates CJ, George AL Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007;15:139-45
   PubMed Web of Science ®Google Scholar
• Jensen MC, Clarke P, Tan G, Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000;1:49-55
   PubMed Web of Science ®Google Scholar
• Wilkie S, Burbridge SE, Chiapero-Stanke L, Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 2010;285:25538-44
   PubMed Web of Science ®Google Scholar
• Hombach A, Kohler H, Rappl G, Abken H. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol 2006;177:5668-75
   PubMed Web of Science ®Google Scholar
• Moeller M, Haynes NM, Kershaw MH, Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Hawkins RE, Batha H, Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother 2009;32:207-18
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-83
   PubMed Web of Science ®Google Scholar
• Rischer M, Pscherer S, Duwe S, Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol 2004;126:583-92
   PubMed Web of Science ®Google Scholar
• Kondo M, Sakuta K, Noguchi A, Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842-56
   PubMed Web of Science ®Google Scholar
• Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 2008;134:2014-24
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Al-Kadhimi Z, Serrano LM, Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005;105:1622-31
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20:1221-7
   PubMed Web of Science ®Google Scholar
• Roessig C, Scherer SP, Baer A, Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol 2002;81(Suppl 2):S42-3
   PubMedGoogle Scholar
• Savoldo B, Rooney CM, Di Stasi A, Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110:2620-30
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Myers GD, Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009;114:4283-92
   PubMed Web of Science ®Google Scholar
• Baylor College of Medicine. Study of the T-cells or EBV Specific CTLs for Advanced B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. ClinicalTrials.gov NCT00709033. Available from: http://clinicaltrials.gov/ct2/show/NCT00709033?term=NCT00709033&rank=1
   Google Scholar
• Lefrancois L, Obar JJ. Once a killer, always a killer: from cytotoxic T cell to memory cell. Immunol Rev 2010;235:206-18
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Cassard L, Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009;106:17469-74
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305
   PubMed Web of Science ®Google Scholar
• Lamers CH, Willemsen R, van Elzakker P, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011;117:72-82
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; In press
   Google Scholar
• Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007;19:318-30
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli Al, CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-12
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9
   PubMed Web of Science ®Google Scholar
• Wallen H, Thompson JA, Reilly JZ, Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 2009;4(3):e4749
   PubMedGoogle Scholar
• Wrzesinski C, Paulos CM, Kaiser A, Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1-7
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006;29:313-19
   PubMed Web of Science ®Google Scholar
• Pouw N, Treffers-Westerlaken E, Kraan J, Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother 2010;59:921-31
   PubMed Web of Science ®Google Scholar
• Vera JF, Hoyos V, Savoldo B, Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009;17:880-8
   PubMed Web of Science ®Google Scholar
• Vo DD, Prins RM, Begley JL, Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009;69:8693-9
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010;184:6938-49
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004;173:7647-53
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113:6392-402
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Foster AE, Dotti G, Lu A, Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008;31:500-5
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Vera JF, Savoldo B, Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007;110:2793-802
   PubMed Web of Science ®Google Scholar
• Hombach AA, Kofler D, Rappl G, Abken H. Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther 2009;16:1088-96
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20-2
   PubMedGoogle Scholar
• Kochenderfer JN, Wilson WH, Janik JE, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-42
   PubMed Web of Science ®Google Scholar
• Westwood JA, Murray WK, Trivett M, Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther 2008;15:1056-66
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6
   PubMed Web of Science ®Google Scholar
• Brentjens R, Yeh R, Bernal Y, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol Ther 2010;18:666-8
   PubMed Web of Science ®Google Scholar
• Vera J, Savoldo B, Vigouroux S, T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890-7
   PubMed Web of Science ®Google Scholar
• Ramos CA, Asgari Z, Liu E, An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 2010;28:1107-15
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonini C, Stanghellini MT, Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009;10(5):489-500
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-24
   PubMed Web of Science ®Google Scholar
• Meier R, Golovko D, Tavri S, Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magn Reson Med 2011;65:756-63
   PubMed Web of Science ®Google Scholar
• Daly T, Royal RE, Kershaw MH, Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000;7:284-91
   PubMed Web of Science ®Google Scholar
• McGuinness RP, Ge Y, Patel SD, Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999;10:165-73
   PubMed Web of Science ®Google Scholar
• Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 1998;77:181-7
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Topp MS, Serrano LM, T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003;101:1637-44
   PubMed Web of Science ®Google Scholar
• Loskog A, Giandomenico V, Rossig C, Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20:1819-28
   PubMed Web of Science ®Google Scholar
• Jensen M, Tan G, Forman S, CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998;4:75-83
   PubMedGoogle Scholar
• Hombach A, Heuser C, Sircar R, An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 1998;58:1116-19
   PubMed Web of Science ®Google Scholar
• Yun CO, Nolan KF, Beecham EJ, Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000;2:449-59
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Debets R, Chames P, Bolhuis RL. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003;64:56-68
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Ronteltap C, Chames P, T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-8
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Naranjo A, Serrano LM, Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004;6:704-11
   PubMed Web of Science ®Google Scholar
• Rossig C, Bollard CM, Nuchtern JG, Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001;94:228-36
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15
   PubMed Web of Science ®Google Scholar
• Mezzanzanica D, Canevari S, Mazzoni A, Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther 1998;5:401-7
   PubMed Web of Science ®Google Scholar
• Westwood JA, Smyth MJ, Teng MW, Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005;102:19051-6
   PubMed Web of Science ®Google Scholar
• Morgenroth A, Cartellieri M, Schmitz M, Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007;67:1121-31
   PubMed Web of Science ®Google Scholar
• Gong MC, Latouche JB, Krause A, Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-7
   PubMedGoogle Scholar
• Gattenlohner S, Marx A, Markfort B, Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. Cancer Res 2006;66:24-8
   PubMed Web of Science ®Google Scholar
• Darcy PK, Kershaw MH, Trapani JA, Smyth MJ. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 1998;28:1663-72
   PubMed Web of Science ®Google Scholar
• Haynes NM, Trapani JA, Teng MW, Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-6
   PubMed Web of Science ®Google Scholar
• Sheen AJ, Sherlock DJ, Irlam J, T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 2003;88:1119-27
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach AA, Abken H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 2011;18:62-72
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Waks T, Kaufman-Francis K, Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003;63:2470-6
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Waks T, Malina V, Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-81
   PubMed Web of Science ®Google Scholar
• Stancovski I, Schindler DG, Waks T, Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993;151:6577-82
   PubMed Web of Science ®Google Scholar
• Teng MW, Kershaw MH, Moeller M, Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther 2004;15:699-708
   PubMed Web of Science ®Google Scholar
• Altenschmidt U, Kahl R, Moritz D, Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996;2:1001-8
   PubMed Web of Science ®Google Scholar
• Hekele A, Dall P, Moritz D, Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 1996;68:232-8
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Theoret MR, Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010;120:3953-68
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Zhu Z, Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther 2000;11:2445-52
   PubMed Web of Science ®Google Scholar
• Niederman TM, Ghogawala Z, Carter BS, Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 2002;99:7009-14
   PubMed Web of Science ®Google Scholar